Related Experiment Videos
Rational promoter selection for gene transfer into cardiac cells
Alexander Maass1, Stephen J Langer, Silke Oberdorf-Maass
1Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Campus Box 347, Boulder, CO 80309 0347, USA.
Journal of Molecular and Cellular Cardiology
|June 24, 2003
Summary
Researchers compared three promoters (CMV, RSV, MEF2) for gene expression in cardiac cells using adenoviruses. CMV offered inducible expression, RSV showed myocyte enrichment, and MEF2 provided stable control, guiding future cardiac gene therapy strategies.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- Gene Therapy
Background:
- Non-viral transfection of cardiomyocytes (CMCs) is challenging; adenoviruses offer efficient infection.
- Viral promoters are commonly used for constitutive protein expression in cardiac myocytes.
- Understanding promoter activity is crucial for effective gene delivery in cardiac research.
Purpose of the Study:
- To systematically compare the activity and regulation of CMV, RSV, and a synthetic MEF2-responsive promoter in cardiac cells.
- To evaluate promoter performance in both neonatal and adult rat cardiomyocytes and cardiac fibroblasts.
- To assess the potential of these promoters for inducible and cell-specific gene expression in the heart.
Main Methods:
- Recombinant adenoviruses were constructed using CMV, RSV, and MEF2 promoters.
- Promoter activity was measured in primary neonatal and adult rat cardiomyocytes and cardiac fibroblasts.
- Cells were treated with agonists like PMA, forskolin, and phenylephrine to assess inducibility.
- Reporter gene expression and troponin T (TnT) replacement were quantified.
Main Results:
- CMV promoter showed significant induction (up to 60-fold) by PMA/forskolin in neonatal cells but not adult CMCs.
- RSV promoter demonstrated higher activity in cardiac myocytes than fibroblasts, with minimal agonist effect.
- MEF2 promoter exhibited high basal expression in both cell types, with negligible induction.
- CMV promoter driving TnT allowed for >15-fold induction with phenylephrine/forskolin, nearly replacing endogenous protein.
Conclusions:
- The CMV promoter is suitable for inducible gene expression systems in cardiac cells.
- The RSV promoter is advantageous for myocyte-enriched gene expression.
- The MEF2 promoter serves as a stable control system for cardiac gene expression studies.
- These findings provide a framework for selecting appropriate promoters in cardiac gene therapy and research.